LA JOLLA, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, President and CEO of Immunosyn Corporation (OTC:IMYN) (BULLETIN BOARD: IMYN) , will present to a diverse group of investors, portfolio managers and analysts at the Flaherty Financial/Wall Street Research Small Cap Conference on January 22, 2008 at The Penn Club in New York City. A webcast of the presentation will be available and archived for 60 days at http://www.visualwebcaster.com/event.asp?=42359. "We are privileged to present Immunosyn to the elite group of investors, industry experts and analysts at the Flaherty Financial News/Wall Street Research Small Cap Conference," says Ferrone. "This is a great opportunity to increase market awareness for Immunosyn, to articulate our vision and goals and to show the ways in which we are moving closer to achieving them." Immunosyn's objectives, overview and product information will be communicated to target audiences at select conferences such as the Flaherty Financial/Wall Street Research Small Cap Conference. Presentations will be made which include market data, research information and milestones achieved. As part of Immunosyn's presentation, Ferrone will focus on the biopharmaceutical SF-1019, including information about the steps being taken toward regulatory approvals and results of a recent trial. About Flaherty Financial News Flaherty Financial News is the publisher of totally-electronic coverage of the neglected micro- and small-cap markets with Flaherty Financial News Newsletter and Flaherty Special Situations. Both were recently launched by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, who serves as President and Publisher. To opt in for future issues please visit http://www.flahertyfinancialnews.com/ and log in. About WallStreet Research WallStreet Research (WSR) is a prominent research boutique led by Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the micro- and small- cap investment arena, seeking emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength and outstanding long-term earnings growth possibilities. WSR has offices in Los Angeles, CA, Palm Beach, FL and New York City, NY. About Immunosyn Corporation La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com/) The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise. For further information, contact: Bill Kraus/Lisa Baker/Devon Blaine The Blaine Group 310/360-1499 310/360-1498 (FAX) DATASOURCE: Immunosyn Corporation CONTACT: Bill Kraus or Lisa Baker or Devon Blaine of The Blaine Group, +1-310-360-1499, fax, +1-310-360-1498, , for Immunosyn Corporation Web site: http://www.immunosyn.com/

Copyright